Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Spotify Technology (SPOT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Spotify Technology — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Spotify Technology trades at $488.95 (market cap $101.57B). The key difference: Spotify Technology is far larger — about 22.6× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Spotify Technology nearer its low. Which is the better fit depends on your goals.
| ACAD | SPOT | |
|---|---|---|
Market Cap | $4.49B | $101.57B |
Sector | Health | Media |
52-Week High | $28.06 | $738.53 |
52-Week Low | $20.06 | $412.75 |
Enterprise Value | $3.69B | $92.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Spotify (SPOT) trades at $493.95, up 1.64% with a bullish technical outlook. The stock shows strong fundamentals with revenue growth from $11.7B in 2022 to $17.2B in 2025 and net income turning positive to $2.2B. Analyst consensus is bullish with a $623 price target, supported by recent earnings beats. Key resistance is near $499, while support holds at $477.
Outlook remains positive driven by margin expansion and platform diversification, but risks include competition and market volatility. The stock offers growth potential with a 26% upside to consensus target, though investors should monitor execution on profitability goals amid rising content costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
